PHAT logo

PHAT
Phathom Pharmaceuticals Inc

2,356
Mkt Cap
$1.06B
Volume
1.42M
52W High
$18.31
52W Low
$2.21
PE Ratio
-4.22
PHAT Fundamentals
Price
$12.88
Prev Close
$13.47
Open
$13.51
50D MA
$11.63
Beta
1.21
Avg. Volume
1.14M
EPS (Annual)
-$3.03
P/B
-2.10
Rev/Employee
$471,994.61
$1,668.92
Loading...
Loading...
News
all
press releases
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8% - Time to Sell?
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from Analysts
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat.com...
MarketBeat·8d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT
Hennion & Walsh Asset Management Inc. bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 114,981 shares of the company's stock, valued at appro...
MarketBeat·20d ago
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Analyst Upgrade...
MarketBeat·26d ago
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays
Barclays raised shares of Phathom Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $16.00 to $18.00 in a report on Friday...
MarketBeat·26d ago
News Placeholder
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Zacks·28d ago
News Placeholder
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.
Zacks·29d ago
News Placeholder
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. One...
MarketBeat·1mo ago
News Placeholder
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
Zacks·1mo ago
News Placeholder
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
Zacks·1mo ago
<
1
2
...
>

Latest PHAT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.